In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Many targeted therapies, such as trastuzumab, lapatinib and bevacizumab, have proven efficacy in combination with chemotherapy and only limited activity as monotherapy. For many patients ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Dose-dense AC every 2 weeks (four-times)then dose-dense ABI-007 260 mg/m 2 every 2 weeks (four-times) plus Bevacizumab (10 ... including in combination with trastuzumab, which is in ongoing ...